ETON
HealthcareEton Pharmaceuticals, Inc. · Biotechnology · $890M
What is Eton Pharmaceuticals, Inc.?
Eton Pharmaceuticals is a specialty pharmaceutical company focused on developing and commercializing treatments for rare diseases. Incorporated in 2018 and headquartered in Deer Park, Illinois, the company targets underserved patient populations with niche, often pediatric-focused therapies.
Eton Pharmaceuticals generates revenue by bringing specialty drug formulations to market — particularly for rare or orphan conditions where few alternatives exist. The company acquires, develops, and commercializes products addressing gaps in hospital and outpatient settings. Its portfolio spans injectable treatments for anesthesia-related hypotension, hormone replacement therapies for children, and oral liquid formulations for seizure disorders. Rather than pursuing large primary-care markets, Eton concentrates on smaller, high-need patient groups where regulatory pathways and pricing dynamics can be more favorable.
Eton Pharmaceuticals was incorporated in 2018 and operates out of Deer Park, Illinois.
- Biorphen and Rezipres — injectable treatments for anesthesia-related hypotension
- Alkindi Sprinkle — adrenocortical insufficiency replacement therapy for children
- EPRONTIA — liquid topiramate formulation for seizure management
- Carglumic Acid — treatment for a rare metabolic enzyme deficiency
- Alaway Preservative Free — ophthalmic drop for allergic conjunctivitis
Is ETON a Good Stock to Buy?
UQS Score rates ETON as Below Average overall.
The standout element in Eton's profile is its Growth pillar, which registers as Strong — reflecting the company's expanding rare-disease portfolio and commercial momentum. The Risk pillar also lands in Good territory, suggesting the balance sheet and operational risk profile are relatively manageable for a small-cap specialty pharma.
Both the Quality and Moat pillars are rated Weak, pointing to limited earnings durability and a narrow competitive advantage relative to peers. Valuation sits at Neutral, offering neither a clear discount nor a significant premium signal.
Pro members can view the exact pillar breakdown and full financial metrics behind the ETON UQS Score. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does ETON pay dividends?
No — Eton Pharmaceuticals, Inc. does not currently pay a dividend.
Eton Pharmaceuticals does not currently pay a dividend. For an early-stage specialty pharma company, this is typical — available capital is directed toward pipeline development, product launches, and commercial infrastructure rather than shareholder distributions. Investors in ETON are generally seeking growth from portfolio expansion rather than income.
When does ETON report earnings?
Eton Pharmaceuticals reports earnings on a quarterly cadence, consistent with standard practice for US-listed equities.
Eton's recent reporting periods have reflected the dynamics of a company scaling its commercial portfolio — revenue trends tied closely to product uptake across its rare-disease lineup. Profitability metrics remain a focus area given the Weak Quality pillar rating.
For the most recent quarter's results and guidance, visit Eton Pharmaceuticals' investor relations page directly.
ETON Price History
+233.4% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Eton Pharmaceuticals, Inc.?
Based on Eton Pharmaceuticals, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
ETON Long-term Outlook
Eton's Strong Growth pillar suggests the company's rare-disease portfolio has meaningful commercial runway ahead, driven by continued product adoption and potential pipeline additions. However, the Weak Quality and Moat ratings temper the outlook — sustained profitability and defensible market positioning remain open questions. The Good Risk rating provides some reassurance that near-term financial stability is not a primary concern, but the path to durable earnings quality will be a key factor for long-term investors.
Growth drivers
- Expanding commercial adoption of existing rare-disease products
- Pipeline additions targeting underserved orphan-disease indications
- Favorable regulatory and pricing dynamics in niche specialty markets
Key risks
- Weak Moat rating signals limited pricing power and competitive barriers
- Weak Quality pillar reflects earnings inconsistency typical of early commercialization
- Small-cap specialty pharma faces concentration risk if key products underperform
ETON vs Peers
Eton operates in a competitive rare-disease and specialty pharma space alongside a range of development-stage and commercial-stage peers.
Prime Medicine focuses on next-generation gene editing technology rather than commercial specialty drug formulations, placing it at an earlier and more technology-driven stage than Eton.
Solid Biosciences concentrates on gene therapy for Duchenne muscular dystrophy, representing a single-disease focus with a distinct therapeutic modality compared to Eton's multi-product rare-disease portfolio.
BioAge Labs targets the biology of aging as a disease driver, pursuing a platform-based discovery approach that differs from Eton's strategy of commercializing established drug formulations for rare conditions.
Frequently Asked Questions
What does Eton Pharmaceuticals do?
Eton Pharmaceuticals is a specialty pharma company that develops and sells treatments for rare diseases. Its marketed products include injectable hospital drugs, pediatric hormone therapies, and oral liquid formulations for seizure disorders. The company focuses on niche patient populations where standard formulations are unavailable or inadequate.
Does ETON pay dividends?
No, Eton Pharmaceuticals does not currently pay a dividend. The company reinvests available resources into its commercial portfolio and pipeline development. Investors in ETON are typically seeking capital appreciation from product growth rather than dividend income.
When does ETON report earnings?
Eton Pharmaceuticals follows a standard quarterly earnings cadence for US-listed companies. Specific upcoming report dates are not covered by our data source — check Eton's investor relations page for the current schedule.
Is ETON a good stock to buy?
UQS Score rates ETON as Below Average overall. The Growth pillar is Strong and Risk is Good, but Quality and Moat are both Weak. Whether that profile suits your portfolio depends on your risk tolerance and investment horizon. The full pillar breakdown is available to Pro members.
Is ETON overvalued?
ETON's Valuation pillar is rated Neutral, meaning the current price is neither clearly discounted nor significantly stretched relative to the UQS framework. For investors, this suggests valuation alone is not the dominant factor — quality and moat concerns carry more weight in the overall Below Average rating.
How does ETON compare to its competitors?
Eton's peers in the rare-disease and specialty biotech space — including Prime Medicine, Solid Biosciences, and BioAge Labs — each pursue distinct therapeutic strategies. Eton differentiates itself through a multi-product commercial portfolio rather than a single-disease or platform-technology focus. See the competitor section above for more detail.
What is ETON's market cap bracket?
Eton Pharmaceuticals is classified as a small-cap company. This places it in a segment of the market characterized by higher growth potential but also greater volatility and liquidity risk compared to mid- or large-cap peers in the healthcare sector.
Who founded Eton Pharmaceuticals?
Eton Pharmaceuticals was incorporated in 2018. Founding and leadership details are publicly available through the company's SEC filings and investor relations materials for those seeking background on the management team.
Is ETON a long-term quality investment?
As a long-term quality indicator, ETON's Below Average UQS Score — driven by Weak Quality and Moat pillars — suggests the company has not yet demonstrated the earnings durability or competitive defensibility associated with high-quality long-term holdings. The Strong Growth pillar is a positive signal, but sustained quality improvement would be needed to shift that overall rating.
What is the main competitive advantage of Eton Pharmaceuticals?
Eton's strategy centers on identifying underserved rare-disease niches where it can commercialize specialty formulations with limited direct competition. However, the Weak Moat pillar rating in the UQS framework indicates this advantage is not yet considered durable or wide relative to sector peers.
What sector does ETON belong to?
Eton Pharmaceuticals operates in the Healthcare sector, specifically within specialty and rare-disease pharmaceuticals. Investors can explore other [healthcare sector stocks](/sector/healthcare) rated by UQS Score for broader context.
Is ETON a growth stock or value stock?
Based on UQS pillar labels, ETON leans toward growth — the Growth pillar is rated Strong while Valuation is Neutral. This profile is typical of a commercial-stage specialty pharma company investing heavily in portfolio expansion, where near-term earnings quality trails revenue momentum.
Unlock Full ETON Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the exact UQS Score and all five pillar ratings
- ✓Access full financial metrics and trend data
- ✓Compare ETON against rare-disease and specialty pharma peers
- ✓See the complete Quality and Moat breakdown in detail
- ✓Track score changes as new earnings data arrives
- ✓Explore curated screens for [small-cap healthcare stocks](/preset/small-cap-healthcare)
Pro Analysis
ETON — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 22, 2026 | 44.5 | 23.6 | 22.0 | 85.8 | 64.1 | 42.4 | +0.9 |
| May 11, 2026 | 43.6 | 16.7 | 22.0 | 85.8 | 68.2 | 43.7 | +3.5 |
| May 10, 2026 | 40.1 | 0.1 | 22.0 | 85.8 | 36.9 | 79.4 | +0.2 |
| May 8, 2026 | 39.9 | 0.1 | 22.0 | 85.8 | 36.9 | 77.9 | -3.5 |
| May 7, 2026 | 43.4 | 16.7 | 22.0 | 85.8 | 68.2 | 42.3 | -0.1 |
| May 3, 2026 | 43.5 | 16.7 | 22.0 | 85.8 | 68.2 | 43.0 | -0.7 |
| Apr 26, 2026 | 44.2 | 16.7 | 22.0 | 85.8 | 68.2 | 47.6 | +0.3 |
| Apr 19, 2026 | 43.9 | 16.7 | 22.0 | 85.8 | 68.2 | 45.8 | +0.1 |
| Apr 18, 2026 | 43.8 | 16.7 | 22.0 | 85.8 | 68.2 | 45.2 | -1.7 |
| Apr 14, 2026 | 45.5 | 16.7 | 22.0 | 85.8 | 68.2 | 56.5 | +0.1 |
ETON — Pillar Breakdown
Quality
— 23.6/100 (25%)Eton Pharmaceuticals, Inc. currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 85.8/100 (20%)Eton Pharmaceuticals, Inc. is growing rapidly with strong revenue and earnings expansion.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Analyst consensus for future earnings growth.
Risk
— 64.1/100 (15%)Eton Pharmaceuticals, Inc. maintains a reasonable risk profile with manageable debt levels.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 42.5/100 (15%)Eton Pharmaceuticals, Inc. has a mixed valuation — some metrics suggest fair value while others appear stretched.
Inverse of forward P/E — higher yield means cheaper stock.
How many years of FCF the market cap represents.
P/E relative to earnings growth — lower is more attractive.
Enterprise value multiple relative to sector median.
Moat
— 22/100 (25%)Eton Pharmaceuticals, Inc. operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for ETON.
Score Composition
Financial Data
More Stock Analysis
How is the ETON UQS Score Calculated?
The UQS (Unified Quality Score) for Eton Pharmaceuticals, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Eton Pharmaceuticals, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Eton Pharmaceuticals, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.